Insmed Incorporated (NASDAQ:INSM) CEO Sells $188,686.08 in Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 2,978 shares of the firm’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $63.36, for a total transaction of $188,686.08. Following the completion of the sale, the chief executive officer now owns 392,589 shares in the company, valued at $24,874,439.04. This represents a 0.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

William Lewis also recently made the following trade(s):

• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total transaction of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total transaction of $1,310,812.50.

Insmed Stock Performance

Insmed stock traded down $0.47 during trading hours on Friday, reaching $65.25. 3,087,759 shares of the stock were exchanged, compared to its average volume of 1,881,810. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53. The stock has a market cap of $11.67 billion, a P/E ratio of -11.76 and a beta of 1.12. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm’s 50 day moving average is $71.29 and its 200 day moving average is $72.44.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to analysts’ expectations of $93.36 million. During the same period in the prior year, the firm posted ($1.10) EPS. The firm’s revenue for the quarter was up 18.1% compared to the same quarter last year. Analysts predict that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of recent research reports. Truist Financial reiterated a “buy” rating and issued a $105.00 price objective (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. JPMorgan Chase & Co. boosted their price objective on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research note on Friday, November 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Insmed in a research note on Friday, November 1st. Finally, Bank of America boosted their target price on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and an average price target of $83.67.

Institutional Trading of Insmed

A number of institutional investors have recently modified their holdings of INSM. Orion Portfolio Solutions LLC boosted its position in shares of Insmed by 48.5% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock worth $2,050,000 after purchasing an additional 9,170 shares in the last quarter. Ally Bridge Group NY LLC boosted its holdings in Insmed by 16.9% during the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock worth $11,011,000 after buying an additional 21,833 shares in the last quarter. Vestal Point Capital LP grew its position in Insmed by 113.3% during the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after buying an additional 850,000 shares during the period. TimesSquare Capital Management LLC acquired a new stake in shares of Insmed during the 3rd quarter valued at approximately $35,322,000. Finally, Jennison Associates LLC boosted its stake in shares of Insmed by 3.4% during the 3rd quarter. Jennison Associates LLC now owns 769,253 shares of the biopharmaceutical company’s stock worth $56,155,000 after acquiring an additional 24,973 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.